IL22 and Alzheimer disease: Considering IL-17C as a potential therapeutic target in AD can be interesting given the great clinical heterogeneity of AD, which reflects a variable interaction on the molecular level of the Th2 pathway with other cytokines more expressed in Th1-type pathways such as IL-17 and IL-22.